Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained
How the Roche Board Managed the Genentech Acquisition
In 2009, Roche faced a pivotal decision: acquire the 44% of Genentech it didn't already own for $46.8 billion. Genentech's board resisted fiercely, demanding a higher price and threatening to walk away. This episode dissects how Roche's board navigated the hostile takeover, the cultural clash between Swiss pharma and Silicon Valley biotech, and the strategic rationale that ultimately justified the premium. Lucas and Luna explore the governance lessons from one of biotech's defining boardroom battles, including how Roche preserved Genentech's innovation engine while…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.